Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TUM012 Ex-Vivo Treatment in Kidney Transplantation
NCT05246618Phase 2Completed
- Sponsor
- iCoat Medical
- Start
- Mar 2022
- Primary completion
- Jul 2023
- Modality
- Polymer-based Nanoparticles
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of iCM012 in ischemia-reperfusion injury (IRI), sponsored by iCoat Medical. Primary endpoints: Adverse Events at 3 months, Laboratory Analyses (Standard of Care Safety) at 3 months and 5 more. Started Mar 2022; status: completed.
02
Drugs
iCM012
03
Conditions
ischemia-reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT05246618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05246618.